Table III.
Overview of treatments (including chemotherapy and stem cell transplantation) patients received prior to and after T0 (n=65).
| Treatment | Pre T0 N (%) |
Post T0 N (%) |
|---|---|---|
| Median (range) of lines of therapy | 5 (1-11) | 2 (0-6) |
| Bortezomib in any combination | 65 (100%) | 20 (31%) |
| Lenalidomide in any combination | 65 (100%) | 15 (23%) |
| VRD | 20 (31%) | 5 (8%) |
| Thalidomide | 41 (63%) | 2 (3%) |
| Anthracyclines | 30 (46%) | 9 (14%) |
| Doxil | 24 (37%) | 7 (11%) |
| Doxorubicin | 6 (9%) | 2 (3%) |
| Alkylators | 24 (37%) | 36 (55%) |
| Melphalan (conventional dose, excluding transplant) | 12 (18%) | 7 (11%) |
| Cyclophosphamide | 14 (22%) | 28 (43%) |
| Bendamustine | 3 (5%) | 21 (32%) |
| DCEP | 1 (2%) | 7 (11%) |
| M2 | 0 | 5 (8%) |
| Carfilzomib or pomalidomide | 10 (15%) | 22 (34%) |
| Carfilzomib | 9 (14%) | 11 (17%) |
| Pomalidomide | 2 (3%) | 15 (23%) |
| Elotuzumab | 1 (2%) | 2 (3%) |
| Other investigational agents | 14 (22%) | 13 (20%) |
| Stem cell transplantation | 48 (74%) | 9 (14%) |
| Autologous transplant | 48 (74%) | 5 (8%) |
| Allogeneic transplant | 0 | 4 (6%) |
Abbreviations: VRD- bortezomib, lenalidomide, and dexamethasone; DCEP- dexamethasone, cyclophosphamide, etoposide, and cisplatin; M2- vincristine, carmustine, cyclophosphamide, melphalan, and prednisone.